Median incomes have not kept pace with the inflation rate for job-based health insurance costs, straining family budgets. » Read More
Endo International shares surged after it posted second-quarter earnings that exceeded analysts expectations and appointed new management.
Valeant Pharmaceuticals reported quarterly earnings and revenue that fell short of analysts' expectations on Tuesday.
A record-setting $5.55 million settlement this month came after two settlements totaling close to that amount in July.
The U.S. Food and Drug Administration issued its final word on a trial for the genetically-modified Oxitec mosquito in Florida.
Shares of Bristol-Myers Squibb briefly fell more than 17 percent in opening trade Friday after its cancer drug failed to meet targets in a late-stage study.
The opioid drug crisis could become a big hurdle for states wooing businesses by touting their great quality of life and workforce.
Illinois-based Advocate Health Care Network will pay $5.55 million to federal regulators.
Medicare open enrollment is coming up. Find out how you can save on coverage and out-of-pocket costs.
Recent studies suggest the effects of the Zika virus on fetuses may be worse than thought, Dr. Scott Gottlieb says.
More than 1,300 patients identified as at-risk of Zika are served by a single health-care facility.
Less than 1,500 people in Athenahealth's cloud network of patient records have been tested for Zika.
Patients missing out on their medication or taking the wrong dose costs the U.S. health care system $290 billion each year, according to a new report.
CVS Health's new "excluded" list includes medications used in treatment of patients with cancer, diabetes and hepatitis C.
Biogen shares soared on reports the company has drawn takeover interest from rival companies, the Wall Street Journal said.
CDC Director Tom Frieden says pregnant women all over the South should protect themselves against mosquito bites because of the risk of Zika.
Pfizer's results were driven by lower taxes and demand for new medicines, but it stuck to its previous sales and profit forecasts for the full year.
Get the best of CNBC in your inbox